ClinicalTrials.gg
CompletedNCT03688022MT-7117 BA DDIUpdated May 15, 2023

Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor

A Phase 1 interventional study of MT-7117 and PPI in Healthy Volunteer, sponsored by Mitsubishi Tanabe Pharma America Inc.. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Mitsubishi Tanabe Pharma America Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

An open label, multicentre, randomised, 2-cohort, sequential and crossover study to assess the relative oral bioavailability of MT-7117 higher content tablets versus MT-7117 lower content tablets and the pharmacokinetics of MT-7117 under various gastric conditions (fed and fasted, and following administration of a proton pump inhibitor and an acidic beverage) in healthy subjects

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Relative Bioavailability and DDI study with MT-7117 and a proton pump inhibitor
03

In context

Lead sponsor

Mitsubishi Tanabe Pharma America Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Additional screening criteria check may apply for qualification:

  • Able to provide written to participate in this study.
  • Healthy and free from illness or disease.
  • Caucasian male and female subjects aged 18 to 55 years (inclusive) that are willing and able to practice acceptable for the duration of the study, as defined in the Protocol.
  • A body weight of ≥50.0 kg and a (BMI) (Quetelet index) ranging from 18.0 to 30.0 kg/m2 (inclusive) at Screening.
  • Subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements.

Exclusion criteria

Exclusion Criteria:

Additional screening criteria check may apply for qualification:

  • Previously having received MT-7117.
  • Participation in more than 3 clinical studies* involving administration of an Medicinal Product (IMP) in the previous year, or any study* involving administration of an IMP within 12 weeks (or, if relevant, 5 half-lives, whichever is the longer) prior to the first dose. (*Disregarding any study Follow-up Periods).
  • Subjects who have received any prescribed systemic or topical medication within 14 days (or, if relevant, 5 half-lives; whichever is longer) prior to the first dose of IMP.
  • Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days (or, if relevant, 5 half-lives; whichever is longer) prior to the first dose of IMP.
  • abnormal medical history.
  • Family history of long or short syndrome, hypokalaemia, syncope or Torsades de Pointes.
  • Clinically significant 12-lead (ECG) abnormalities.
  • Blood pressure (supine) at Screening outside the range 90 to 140 mmHg (systolic) or 50 to 90 mmHg (diastolic).
  • Presence or history of severe adverse reaction or allergy to any drug.
  • Presence or history of drug abuse.
  • Presence or history of alcohol abuse.
  • Subjects who use tobacco or nicotine-containing products within 3 months.
  • Test positive for surface antigen, hepatitis B core antibody, antibody, or (HIV) 1 \& HIV 2 antibodies.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    MT-7117 BA and DDI (fasted)

    MT-7117 lower content tablets, higher content tablets, higher content tablets with PPI (fasted), higher content tablets with PPI and acidic beverage (fasted)

    Drug: MT-7117 · Drug: PPI · Dietary Supplement: Acidic beverage

  • Experimental
    MT-7117 food effect and DDI (fed)

    MT-7117 higher content tablets (fasted and fed), higher content tablets with PPI (fed), higher content tablets with PPI and acidic beverage (fed)

    Drug: MT-7117 · Drug: PPI · Dietary Supplement: Acidic beverage

Interventions

  • MT-7117

  • DrugPPI

    Proton pump inhibitor

  • Dietary supplementAcidic beverage

    Acidic beverage

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Pre-dose and up to 48 hours following each single dose

  2. Area under the plasma concentration time curve from time zero to last quantifiable concentration (AUC0-t)

    Time frame: Pre-dose and up to 48 hours following each single dose

  3. Area under the plasma concentration time curve from time zero to infinity (AUC0-inf)

    Time frame: Pre-dose and up to 48 hours following each single dose

Secondary outcomes

  1. Incidence of adverse events (AEs) and serious AEs

    Time frame: up to 48 hours post dose

07

Study locations

1 site
  • Investigational Centre(s)
    Germany, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Dec 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2018
First posted
Sep 27, 2018
StartActual
Oct 25, 2018
Primary completionActual
Dec 22, 2018
CompletionActual
Dec 22, 2018
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03688022
Responsible party
Sponsor
First posted
Sep 27, 2018
Start date
Oct 25, 2018
Primary completion
Dec 22, 2018
Completion
Dec 22, 2018
Last update
May 15, 2023

Study contacts

General Manager
study director · Mitsubishi Tanabe Pharma Europe Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion